Zim Laboratories LimitedZIMLABCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data

₹144.76

MCap ₹777 Cr · P/E 210.2

Zim Laboratories Limited — Stock analysis & AI research Zim Laboratories Limited — Seasonality — best & worst months Zim Laboratories Limited — Technical setup — score, trend, support & resistance Zim Laboratories Limited — Live exchange announcements

📈 MACD Bearish Crossover 📈 Strong Trend Stocks (ADX > 25)📈 Bollinger Squeeze Stocks 📈 Bullish EMA Alignment 📈 Relative Strength Leaders 📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹94 Cr

Sales · Jun 2026

+31.2% YoY

₹2 Cr

Operating Profit · Jun 2026

-42.5% YoY

2.6%

OPM % · Jun 2026

-55.9% YoY

₹-4 Cr

Net Profit · Jun 2026

-114.3% YoY

₹-0.75

EPS · Jun 2026

-97.4% YoY

📝 Zim Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Zim Laboratories Limited reported revenue of ₹94 crore for the quarter ended June 2026 (Q1 FY27), up 31.2% from ₹72 crore in the same quarter last year, and down 10.5% sequentially over the March 2026 quarter.

The company reported a net loss of ₹4 crore, against a net loss of ₹2 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.75.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 2.6%, compared with 5.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Zim Laboratories Limited posted revenue of ₹374 crore, a decline of 1.2% over FY25, with a net profit of ₹6 crore (down 52.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹397 crore with a net profit of ₹4 crore.

Valuation snapshot

At the current price of ₹144.76, ZIMLAB has a market capitalisation of ₹777 crore and a trailing P/E of about 210.2.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 30.30%, foreign institutional investors (FIIs) 0.17%, domestic institutional investors (DIIs) 1.19%, public shareholders 68.34% of Zim Laboratories Limited.

Promoter holding slipped from 30.35% to 30.30% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹777 Cr

Current Price ?

₹144.8

P/E ?

210.17above ind

Industry P/E ?

37.20

P/B ?

2.62

P/S ?

1.96

P/FCF ?

70.61

Enterprise Value ?

₹904 Cr

EV/EBITDA ?

32.05

PEG ?

N/A

Earnings Yield ?

0.9%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹397 Cr

OPM ?

7.1%

Profit after tax (TTM) ?

₹4 Cr

EPS (TTM) ?

₹0.69

ROCE ?

5.0%

ROE ?

1.2%

ROA ?

0.7%

Growth

Sales — latest qtr ?

₹94 Cr

PAT — latest qtr ?

₹-4 Cr

YoY qtr sales growth ?

31.2%

YoY qtr profit growth ?

-114.3%

Sales growth (3y) ?

-2%

Sales growth (5y) ?

Profit growth (3y) ?

-44%

Profit growth (5y) ?

-17%

Financial Health

Debt ?

₹127 Cr

Debt to Equity ?

0.43

Interest Coverage ?

0.8

Current Ratio ?

N/A

Ownership

Promoter holding ?

30.30%

Change in promoter holding ?

-2.96%

Pledged percentage ?

N/A

Market

Return 3 months ?

19.6%

Return 6 months ?

82.5%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	105	67	86	96	118	82	92	96	109	72	89	109	105	94	+31.2%	-10.5%
Operating Profit	15	5	9	12	16	8	10	12	15	4	6	13	7	2	-42.5%	-65.9%
Other Income	1	1	1	1	2	1	1	2	2	1	2	2	6	1	-32.8%	-83.9%
Interest	1	2	1	2	2	3	3	3	3	3	3	3	3	4	+10.3%	+10.1%
Depreciation	5	4	4	4	4	5	5	5	5	5	5	5	5	5	+10.5%	+5.3%
Profit Before Tax	10	0	5	7	11	1	3	6	8	-2	-0	6	5	-6	-129.2%	-212.8%
Net Profit	7	0	4	5	8	1	2	4	5	-2	-0	4	4	-4	-114.3%	-207.4%
EPS	1.48	0.05	0.85	0.98	1.66	0.18	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76	-0.75	-97.4%	-198.7%
OPM %	14.7%	7.2%	10.9%	12.0%	13.3%	9.8%	10.3%	12.0%	13.4%	5.9%	6.5%	11.8%	6.8%	2.6%	-55.9%	-61.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹379 Cr	₹374 Cr	₹397 Cr	-1.2%
Operating Profit	₹44 Cr	₹30 Cr	₹28 Cr	-31.4%
OPM %	11.54%	8.02%	7.11%	-30.5%
NPM %	3.21%	1.56%	0.93%	-51.4%
Other Income	₹6 Cr	₹11 Cr	₹11 Cr	+96.8%
Depreciation	₹20 Cr	₹20 Cr	₹20 Cr	-0.7%
Interest	₹11 Cr	₹13 Cr	₹14 Cr	+15.9%
EBIT	₹24 Cr	₹10 Cr	₹8 Cr	-57.5%
PBT	₹18 Cr	₹8 Cr	₹5 Cr	-54.4%
Tax	₹6 Cr	₹2 Cr	₹1 Cr	-59.4%
Net Profit	₹12 Cr	₹6 Cr	₹4 Cr	-52.0%
EPS	₹2.50	₹1.19	₹0.82	-52.4%
Material Cost	₹167 Cr	₹172 Cr	₹187 Cr	+3.0%
Employee Cost	₹61 Cr	₹64 Cr	₹68 Cr	+5.2%
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	49	49	49	54	+10.2%
Reserves	152	190	204	243	+19.1%
Borrowings	62	112	118	127	+7.6%
Other Liabilities	79	96	102	116	+13.7%
Total Liabilities	342	447	472	539	+14.2%
Fixed Assets	109	161	164	162	-1.2%
CWIP	27	42	70	96	+37.1%
Investments	0	0	0	0	—
Other Assets	206	244	237	282	+19.0%
Total Assets	342	447	472	539	+14.2%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	38	16	41	50	+22.0%
Cash from Investing Activity	-36	-73	-40	-55	-37.5%
Cash from Financing Activity	1	60	-9	28	+411.1%
Net Cash Flow	3	3	-8	23	+387.5%
Free Cash Flow	2	-57	1	11	+1000.0%
CFO/OP	87%	46%	92%	177%	+92.4%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	87	100	103	106	+2.9%
Inventory Days	99	173	188	207	+10.1%
Days Payable	107	133	151	161	+6.6%
Cash Conversion Cycle	79	140	140	152	+8.6%
Working Capital Days	67	57	60	41	-31.7%
ROCE %	17%	10%	8%	5%	-37.5%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	33.26%	33.26%	33.26%	30.35%	30.30%	-0.2%
FIIs	0.03%	0.00%	0.02%	0.00%	0.17%	—
DIIs	0.24%	0.24%	0.20%	0.07%	1.19%	+1600.0%
Public	66.46%	66.52%	66.52%	69.57%	68.34%	-1.8%
No. of Shareholders	16,641	17,282	17,251	16,636	13,057	-21.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	ZIMLAB Zim Laboratories	₹131.96	708	161.7	397	4	7.1%	0.9%	-1.2%	-52.0%	31.2%	-114.3%

❓ Frequently asked questions

What was Zim Laboratories Limited's revenue in Q1 FY27?

What was Zim Laboratories Limited's net profit in Q1 FY27?